A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/20/2002	EP1257648A1 Antagonistic selective binding agents of osteoprotegerin binding protein
11/20/2002	EP1257646A2 Transporters and ion channels
11/20/2002	EP1257635A2 Lipid metabolism enzymes and polynucleotides encoding them
11/20/2002	EP1257632A1 Simultaneous stimulation and concentration of cells
11/20/2002	EP1257585A2 Antibodies that bind human interleukin-18 and methods of making and using
11/20/2002	EP1257583A2 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
11/20/2002	EP1257582A2 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
11/20/2002	EP1257581A1 Compounds related to or derived from gfr alpha 4 and their use
11/20/2002	EP1257578A2 Transporters and ion channels
11/20/2002	EP1257576A1 Vasoactive intestinal peptide analogs
11/20/2002	EP1257575A1 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
11/20/2002	EP1257565A1 Mucin-1 derived antigens and their use in immunotherapy
11/20/2002	EP1257563A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
11/20/2002	EP1257560A1 Bcl-2-like polynucleotides, polypeptides, and antibodies
11/20/2002	EP1257556A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
11/20/2002	EP1257555A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
11/20/2002	EP1257546A1 Kinase inhibitors
11/20/2002	EP1257537A1 Therapeutic morpholino-substituted compounds
11/20/2002	EP1257536A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/20/2002	EP1257526A1 Aniline-derived ligands for the thyroid receptor
11/20/2002	EP1257299A2 Radioactive therapeutic liposomes
11/20/2002	EP1257298A1 Cosmid dna constructs and methods of making and using the same
11/20/2002	EP1257297A2 Compositions and methods for treatment of angiogenesis in pathological lesions
11/20/2002	EP1257296A2 Caspase activated prodrugs therapy
11/20/2002	EP1257295A2 Factor vii or viia-like molecules
11/20/2002	EP1257291A1 Novel antibody with specificity for colon cancer
11/20/2002	EP1257289A1 Immunotherapy using interleukin 13 receptor subunit alpha 2
11/20/2002	EP1257285A2 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
11/20/2002	EP1257281A1 Nucleoside analogs with carboxamidine modified monocyclic base
11/20/2002	EP1257270A1 A method for synthesizing leflunomide
11/20/2002	EP1257268A2 Diagnostic and therapeutic compositions and methods for affecting tumor growth using oxygen mimetic agents
11/20/2002	EP1257264A1 Estrogen receptor modulators
11/20/2002	EP1257263A2 Microcompetiton and human disease
11/20/2002	EP1257261A2 Antiviral pharmaceutical compositions containing iron chelators
11/20/2002	EP1147101B1 Reverse hydroxamate inhibitors of matrix metalloproteinases
11/20/2002	EP1042285A4 iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
11/20/2002	EP1003525B1 Composition and method for regulating cell proliferation and cell death
11/20/2002	EP0984784B1 Anti-cancer products for treating cystic fibrosis
11/20/2002	EP0929530B1 Quinazoline derivatives and pharmaceutical compositions containing them
11/20/2002	EP0868174B1 Oral gel capsule formulation of 1,2,4-benzotriazine oxides
11/20/2002	EP0833828B1 Rapamycin derivatives
11/20/2002	EP0758394B1 Bifunctional protein, preparation and use
11/20/2002	EP0656360B1 Trifluoromethylpyrroloindole carboxylic ester derivative and process for producing the same
11/20/2002	EP0572549B1 Use of topotecan in the treatment of non-small cell lung carcinoma
11/20/2002	CN1380882A C10 ester substituted taxanes as antitumor agents
11/20/2002	CN1380420A New-type adenovirus with tumor cell specific infection and transgenic expression capability
11/20/2002	CN1380413A Human 6-phosphoglucosamine isomerase, its code sequence and application
11/20/2002	CN1380407A New human-phosphoguanosine reductase, its coding sequence and application
11/20/2002	CN1380392A Recombinant adenovirus of coexpression human P53 gene and human cytokine gene and its preparation method and application
11/20/2002	CN1380341A Single-stranded cyctic trispecific antibody
11/20/2002	CN1380339A Mutational human gene nucleotide sequence coded polypeptide
11/20/2002	CN1380300A Deoxyribozymeoligonucleotide structure for inhibiting telomerase activity and its application
11/20/2002	CN1380298A Method for separating and extracting total flavone from goldenrain tree plant and its application
11/20/2002	CN1380295A Preparation method of high-purity przewaquinone A
11/20/2002	CN1380288A Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application
11/20/2002	CN1380279A (4-alkynyl), aromatic keto-acid compound, synthesis method and its application
11/20/2002	CN1380107A DNA tumor vaccine and its preparation method
11/20/2002	CN1380106A Thermotherapeutic suppository and its use method
11/20/2002	CN1380104A Biological preparation medicine modulated by micro-alternating biological electric field for curing cancer and its production method
11/20/2002	CN1380103A Biological preparation module by micro-alternating biological electric field for curing benign tumor and its production method
11/20/2002	CN1380089A Anti-cancer medicine and its preparation method
11/20/2002	CN1380077A Programming cell lethal revellent
11/20/2002	CN1094371C Compound medicine for curing leukemia
11/20/2002	CN1094357C Anticancer oral liquid
11/20/2002	CN1094346C Preparation method of microlipid granule for wrapping medicine
11/20/2002	CN1094324C Cancer chemoprotective food products
11/19/2002	US6482986 Benzene derivatives, preparation method and pharmaceutical compositions containing same
11/19/2002	US6482929 Antibodies to ARF-p19
11/19/2002	US6482920 Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
11/19/2002	US6482860 Pentafluorobenzenesulfonamides and analogs
11/19/2002	US6482852 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
11/19/2002	US6482850 Hydrolysis-promoting hydrophobic taxane derivatives
11/19/2002	US6482848 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/19/2002	US6482847 3-(1-methyl-3-indolyl)-4-(1-methyl-6-nitro-3-indolyl)-1h -pyrrole-2,5-dione anticarcinogenic agents
11/19/2002	US6482843 Compounds and methods for use thereof in the treatment of cancer or viral infections
11/19/2002	US6482842 3-aminopyrazole inhibitors of cyclin dependent kinases
11/19/2002	US6482834 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
11/19/2002	US6482832 Heterocyclically substituted amides, their production and their use
11/19/2002	US6482830 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
11/19/2002	US6482822 N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
11/19/2002	US6482816 Organic arsenic compounds
11/19/2002	US6482815 Organic-arsenic compounds
11/19/2002	US6482812 Method of locking 1α-OH of vitamin D compounds in axial orientation
11/19/2002	US6482806 Product of heat treatment of uronic acid, food, drink, or drug including the product
11/19/2002	US6482797 N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE)
11/19/2002	US6482624 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/19/2002	US6482623 Lipid kinase
11/19/2002	US6482618 Self-enhancing, pharmacologically controllable expression systems
11/19/2002	US6482610 Method for producing agents for treating tumor diseases and for immunosuppression
11/19/2002	US6482517 Coated particles, methods of making and using
11/19/2002	US6482407 Membrane-bound cytokine compositions comprising GM-CSF or an active fragment thereof and methods of modulating and an immune response using the same
11/19/2002	US6482405 Antitumor
11/19/2002	CA2272990C Heptapeptide oxytocin analogues
11/19/2002	CA2261579C Isolated peptides derived from mage-2
11/19/2002	CA2252513C Method for the prevention and treatment of cachexia and anorexia
11/19/2002	CA2091700C A non-mitogenic competitive hgf antagonist
11/19/2002	CA2038934C Anti-cancer compounds
11/19/2002	CA1341399C Intercellular adhesion molecules and their binding ligands
11/18/2002	WO2001087878A1 Novel benzothiophene derivatives
11/18/2002	CA2409821A1 Novel benzothiophene derivatives

1 ... 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 ... 2211